Attached files

file filename
EX-31.2 - EX-31.2 - ACHILLION PHARMACEUTICALS INCd398351dex312.htm
EX-10.1 - EX-10.1 - ACHILLION PHARMACEUTICALS INCd398351dex101.htm
EX-32.2 - EX-32.2 - ACHILLION PHARMACEUTICALS INCd398351dex322.htm
EX-31.1 - EX-31.1 - ACHILLION PHARMACEUTICALS INCd398351dex311.htm
EX-10.2 - EX-10.2 - ACHILLION PHARMACEUTICALS INCd398351dex102.htm
EXCEL - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCFinancial_Report.xls
10-Q - FORM 10-Q - ACHILLION PHARMACEUTICALS INCd398351d10q.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Achillion Pharmaceuticals, Inc. (the “Company”) for the quarter ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Michael D. Kishbauch, President and Chief Executive Officer of the Company, hereby certifies, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that:

 

  (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: November 8, 2012  

/s/ Michael D. Kishbauch

  Michael D. Kishbauch
 

President and Chief Executive Officer

(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.